Lantern Pharma (LTRN) Cash & Equivalents (2019 - 2026)

Lantern Pharma (LTRN) has 8 years of Cash & Equivalents data on file, last reported at $4.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 10.78% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (down 10.78% YoY) and the FY2025 annual result came in at $1.5 million, down 76.73% from the prior year.
• Cash & Equivalents rose to $4.9 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $46.7 million in Q1 2022 to a low of $1.3 million in Q4 2022.
• A 5-year average of $18.0 million and a median of $11.5 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 97.53% — and 2023, when it surged 1626.02%.
• Tracing LTRN's Cash & Equivalents over 5 years: stood at $1.3 million in 2022, then surged by 1626.02% to $21.9 million in 2023, then plunged by 69.83% to $6.6 million in 2024, then sank by 76.73% to $1.5 million in 2025, then soared by 219.34% to $4.9 million in 2026.
• The last three Cash & Equivalents figures came in at $4.9 million (Q1 2026), $1.5 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.